TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03282448

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: family therapy
Description: The family-based intervention is informed by Dialectical Behavior Therapy Skills Training for Adolescents (Rathus \& Miller, 2014).
Study: NCT03045289

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Plant-Based Diet
Description: Women will be provided with 3 meals daily, delivered to their home, for 8 weeks, along with a multivitamin, and will attend weekly office visits.
Study: NCT04769089

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Treatment with Pulse Dye Laser
Description: Pulse Dye laser treatment will be applied to one randomized area with the 10mm hand piece, duration of 0.45ms, and fluence of 5.25J/s.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Treatment with CO2 Laser
Description: CO2 laser treatment will be applied to one randomized area with the deep Fx hand piece, 300Hz, 15mJ, 15% density.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Treatment with combination of pulse dye laser and CO2 laser.
Description: Pulse Dye laser and CO2 treatment will be applied to one randomized area. Pulse Dye will be applied with the 10mm hand piece, duration of 0.45ms, and fluence of 5.25J/s followed by the CO2 laser treatment with the deep Fx hand piece, 300Hz, 15mJ, 15% density.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: One area will be randomized to receive no laser treatment.
Study: NCT00839683

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: simvastatin
Description: Tablets, Oral, 20 mg, Single Dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin
Description: Tablets, Oral, 20 mg, Single Dose
Study: NCT04248049

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Platelet rich fibrin
Description: The roots of patients with diagnosis of gingival recessions will be covered with coronally advanced flap (CAF) and platelet rich fibrin (PRF) (CAF+PRF)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Platelet rich fibrin
Description: The roots of patients with diagnosis of gingival recessions will be covered with coronally advanced flap (CAF) and platelet rich fibrin (PRF) (CAF+PRF)
Study: NCT03740932

Intervention type: DIAGNOSTIC_TEST
Intervention: Study group (group A)
Description: Maximal vertical mouth opening (MIO):~From sitting position, with the use of the calliper, the distance between the incisal edges along the midline of the upper and lower central incisors without pain was measured, by placing one end of the poley gauge against the incisal edge of one of the upper central incisors, and the other end against the incisal edge of the opposing lower incisor.~The distance recorded in millimetres, the subjects was instructed to open your mouth as wide as possible without causing pain or discomfort. The poley gauge was sterilized with antiseptic solution before and after each measure

Intervention type: DIAGNOSTIC_TEST
Intervention: Study group (group A)
Description: Maximal vertical mouth opening (MIO):~From sitting position, with the use of the calliper, the distance between the incisal edges along the midline of the upper and lower central incisors without pain was measured, by placing one end of the poley gauge against the incisal edge of one of the upper central incisors, and the other end against the incisal edge of the opposing lower incisor.~The distance recorded in millimetres, the subjects was instructed to open your mouth as wide as possible without causing pain or discomfort. The poley gauge was sterilized with antiseptic solution before and after each measure

Intervention type: DIAGNOSTIC_TEST
Intervention: Study group (group A)
Description: Maximal vertical mouth opening (MIO):~From sitting position, with the use of the calliper, the distance between the incisal edges along the midline of the upper and lower central incisors without pain was measured, by placing one end of the poley gauge against the incisal edge of one of the upper central incisors, and the other end against the incisal edge of the opposing lower incisor.~The distance recorded in millimetres, the subjects was instructed to open your mouth as wide as possible without causing pain or discomfort. The poley gauge was sterilized with antiseptic solution before and after each measure
Study: NCT00839683

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin
Description: Tablets, Oral, 20 mg, Single Dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin
Description: Tablets, Oral, 20 mg, Single Dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: simvastatin
Description: Oral, 40 mg, Single Dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: valsartan
Description: Tablets, Oral, 320 mg, Single Dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: valsartan
Description: Tablets, Oral, 320 mg, Single Dose
Study: NCT03964857

Intervention type: OTHER
Group type: OTHER
Intervention: Refined olive oil (ROO)
Description: Consumption of chicken dishes made with ROO for a period of 8 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blended Oil 1 (BO1)
Description: Consumption of chicken dishes made with BO1 for a period of 8 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blended Oil 2 (BO2)
Description: Consumption of chicken dishes made with BO2 for a period of 8 weeks
Study: NCT02630173

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Scaling and root planing
Description: Scaling and root planing was done in both the groups

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Scaling and root planing
Description: Scaling and root planing was done in both the groups

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Endodontic treatment
Description: In non vital teethRoot canal treatment was completed in two visits. 3% Naocle was used as irritant and calcium hydroxide was used as intracanal medicament .Obturation was done with gutta percha.
Study: NCT03686943

Intervention type: OTHER
Intervention: Family pharmacy
Description: Observation of the family pharmacy in elderly group
Study: NCT03628664

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: CT scan
Description: Assessment of the actual posterior condylar angle using the CT scan
Study: NCT00478777

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Oral lenalidomide at a dose of 25 mg daily for 21 days every 28 days. Treatment as tolerated until disease progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Oral pulse dexamethasone at a dose of 40 mg daily on days 1-4, 9-12, and 17-20 for each 28-day-cycle for cycles 1 through 4 (approximately months 1-4). Beginning cycle 5 (approximately month 5) dexamethasone is reduced to 40 mg daily for days 1-4 every 28 days.
Study: NCT02677571

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Paravertebral Thoracic block

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pectorals nerve block

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levobupivacaine 0.25%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levobupivacaine 0.25%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Study: NCT04547101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK104
Description: AK104，6 mg/kg IV，every 2 weeks (Q2W)
Study: NCT04711018

Intervention type: DIAGNOSTIC_TEST
Intervention: Laryngoscopy
Description: The laryngoscopy is performed with the help of an appropriate size Macintosh blade. The patient's head is held in the sniffing position. External manipulation is not used for improving the view in this investigation.

Intervention type: DIAGNOSTIC_TEST
Intervention: Laryngoscopy
Description: The laryngoscopy is performed with the help of an appropriate size Macintosh blade. The patient's head is held in the sniffing position. External manipulation is not used for improving the view in this investigation.
Study: NCT01898026

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Bread
Description: Samples of white bread, with or without the addition of PGX fibre blend

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bread
Description: Samples of white bread, with or without the addition of PGX fibre blend

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Mashed Potatoes
Description: samples of mashed potatoes, with or without the addition of soluble fibre blend

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mashed Potatoes
Description: samples of mashed potatoes, with or without the addition of soluble fibre blend

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Muffins
Description: Samples of muffins, with or without the addition of PGX fibre blend
Study: NCT02677571

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Study: NCT04242472

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS-based Mobile Health intervention
Description: Nutritional related SMS text message mobile health intervention will be provided to Tuberculosis patients.
Study: NCT00279461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo in arm A and Vitamin D in arm B
Description: Vitamin D3 at 2,000 units daily, all in one capsule, for 6 months and Placebo provided in matching capsule, one capsule daily, for 6 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: vitamin D 3 for arm A ,and matching placebo for arm B
Description: Arm A 2,000 units of Vitamin D3 in one capsule daily for 6 months. Arm B matching placebo capsule, one daily for 6 months
Study: NCT04520542

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupressure Application
Description: Acupressure was administered in a semi-sitting or supine position where the woman felt comfortable and the researcher could perform the practice comfortably to the acupressure points. The application was performed on the determined acupressure points by considering the direction of the meridian in a certain order. It was performed with the administration order of Spleen 6th point (SP 6) and Large Intestine 4th point (Li 4). In total, the administration was performed with 4 acupressure points including 2 points in the upper/lower extremity along with the parallel points in each intervention.
Study: NCT04415164

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xueshuantong lyophilized powder
Description: Xueshuantong lyophilized powder (500mg), diluted with 250 ml of 0.9% sodium chloride injection, IV (in the vein), once a day, continue for 10 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Xueshuantong lyophilized powder Placebo. The usage of placebo is the same as that in the experimental group.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Guidelines-based standard care
Description: Guidelines-based standard care for acute ischemic stroke

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Guidelines-based standard care
Description: Guidelines-based standard care for acute ischemic stroke
Study: NCT00287534

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamoxifen
Description: oral
Study: NCT04467567

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Single Photon Emission Computed Tomography/ Computed Tomography (SPECT/CT)
Description: SPECT/CT will be performed after Lutathera® treatment (at 24h, 96h and 168h after the infusion of Lutathera®) on the conventional camera and on the VERITON-CT camera
Study: NCT03699618

Intervention type: DRUG
Intervention: Anti-VEGF
Description: Standard of care treatment with anti-VEGF only

Intervention type: OTHER
Intervention: Hemorrhage displacement + Anti-VEGF
Description: Standard of care treatment with hemorrhage displacement (at investigators' discretion) followed by anti-VEGF injections
Study: NCT02748356

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactobacillus
Description: Eligible patients will undergo 1 Lactobacillus pediatric dose (Culturelle GG 10 Billion live organisms) instillation by study personnel at the study site. For the intravesicular Lactobacillus instillation, the contents of 1 Lactobacillus capsule will be mixed into sterile 0.9% saline using an age-based estimate of bladder capacity. Similar to adults, this bladder instillation will represent 10% of the estimated maximum bladder volume based on age.
Study: NCT02099890

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vegetation Protein Powder

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: InflanNox

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Anti-oxidant Network

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Chlorella
Study: NCT03258294

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin(Circadin®)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Study: NCT03656068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitazoxanide 500mg BID
Description: Patients will receive 500mg of Nitazoxanide BID daily for 24 weeks
Study: NCT00002875

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lomustine
Study: NCT03939468

Intervention type: DEVICE
Intervention: DES+DCB
Description: A hybrid strategy is defined as overlapping or slightly (2-3 mm) superimposing a new generation DES implantation for a de novo lesion (located in the larger, more proximal part of the vessel) and DCB inflation for a concomitant de novo small vessel disease
Study: NCT03884751

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR-GPC3 T Cells
Description: CAR-GPC3 T Cells injection
Study: NCT01049425

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin
Description: 4 cycles, intravenous use, day 1 every three weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: 4 cycles, intravenous infusion, day 1 every three weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: 4 cycles, intravenous infusion, day 1 every three weeks after completion of EC-chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 6 cycles, intravenous infusion, day 1 every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 6 cycles, intravenous infusion, day one every three weeks
Study: NCT01715987

Intervention type: DRUG
Intervention: Tenofovir Disoproxil Fumarate
Description: 300mg, oral daily for two years

Intervention type: DRUG
Intervention: Entecavir
Description: 0.5mg oral daily for two years.
Study: NCT05361031

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Engensis (VM202)
Description: Intramuscular injections
Study: NCT02742844

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: APZ2 application
Description: Application of IMP on patients wound.
Study: NCT04233216

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISL
Description: ISL 0.75 mg capsule taken by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DOR
Description: DOR 100 mg tablet taken by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DOR/ISL
Description: 100 mg DOR/0.75 mg ISL FDC taken by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DOR/ISL
Description: 100 mg DOR/0.75 mg ISL FDC taken by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DOR/ISL
Description: 100 mg DOR/0.75 mg ISL FDC taken by mouth.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: DOR/ISL
Description: 100 mg DOR/0.75 mg ISL FDC taken by mouth.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to ISL
Description: Placebo capsule matched to ISL taken by mouth.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to DOR
Description: Placebo tablet matched to DOR taken by mouth.
Study: NCT00002875

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mesna
Study: NCT03529604

Intervention type: OTHER
Intervention: Saliva sampling
Description: Saliva was collected from the mouth floor using a specially designed saliva collecting apparatus.

Intervention type: OTHER
Intervention: Saliva sampling
Description: Saliva was collected from the mouth floor using a specially designed saliva collecting apparatus.
Study: NCT00002875

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mesna

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low-LET electron therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low-LET electron therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low-LET photon therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low-LET photon therapy
Study: NCT02040103

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pneumatic compression
Description: All IPC devices intended for DVT prophylaxis are acceptable in the study. Sequential devices (cuffs have several chambers) are preferred, but non-sequential (cuffs have single chambers) are acceptable.
Study: NCT00651261

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cytarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daunorubicin
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: daunorubicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midostaurin
Description: Given orally

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Given orally
Study: NCT03529604

Intervention type: OTHER
Intervention: Saliva sampling
Description: Saliva was collected from the mouth floor using a specially designed saliva collecting apparatus.

Intervention type: DIAGNOSTIC_TEST
Intervention: ELISA
Description: Saliva samples will be analyzed using enzyme-linked immunosorbent assay (ELISA) for the detection of SCCA1, SCCA2 and TROP2.

Intervention type: DIAGNOSTIC_TEST
Intervention: ELISA
Description: Saliva samples will be analyzed using enzyme-linked immunosorbent assay (ELISA) for the detection of SCCA1, SCCA2 and TROP2.

Intervention type: DIAGNOSTIC_TEST
Intervention: ELISA
Description: Saliva samples will be analyzed using enzyme-linked immunosorbent assay (ELISA) for the detection of SCCA1, SCCA2 and TROP2.

Intervention type: DIAGNOSTIC_TEST
Intervention: HPLC
Description: High-performance liquid chromatography (HPLC) will be used to measure Ap4A concentrations in saliva.

Intervention type: DIAGNOSTIC_TEST
Intervention: HPLC
Description: High-performance liquid chromatography (HPLC) will be used to measure Ap4A concentrations in saliva.

Intervention type: DIAGNOSTIC_TEST
Intervention: HPLC
Description: High-performance liquid chromatography (HPLC) will be used to measure Ap4A concentrations in saliva.
Study: NCT04382456

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: acacia gum
Description: Two sachets (à 5 g) in the morning and two sachets in the evening, reconstituted in 120 ml water and stirred until fully dissolved to be taken 10 minutes before meals.
Study: NCT02656797

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical Amphotericin-B 0.4% liposomal gel
Description: Topical Amphotericin-B 0.4% liposomal gel
Study: NCT04388033

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dendritic Cell/Tumor Fusion Vaccine
Description: Vaccine is derived from the participants dendritic cells and tumor cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-12
Description: Given subcutaneously at dose of 6ug twice for interval of one hour.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Following concomitant radiation (2 Gy/day x 30 days) and TMZ-chemotherapy (75 mg/m2/ day x 42 days) , maintenance chemotherapy with TMZ will be administered at 150-200 mg/m2/day for 5 days in each 28-day cycle.
Study: NCT01877759

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Mesenchymal stem cell
Description: Intravenous dose of Mesenchymal stem cell derived from human Bone Marrow \& umbilical cord , IN 6 divided doses , at interval of 1 week .
Study: NCT05213078

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Receive teaching intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT02656797

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Topical Amphotericin-B 0.4% liposomal gel
Description: Topical Amphotericin-B 0.4% liposomal gel
Study: NCT03646786

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality tests
Description: The patient will complete 3 self-questionnaires and pass 3 exploratory tests of virtual reality:~1. 10 minutes sitting test: detection of 5 targets in a 360 ° field of vision~2. 10-minute stand-up motionless test: detection of 5 targets in a 360 ° field of view and placing ingredients of a recipe~3. Standing 10-minute test: the patient moves to the site of his mission, detection of 5 targets in a 360 ° field of vision and preparing a recipe
Study: NCT05213078

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT00162383

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Debrisoquine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mephenytoin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapsone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine
Study: NCT02273141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NER1006, Day Before-Only Dosing
Description: The subject will self-administer both doses of NER1006 in the evening of Day 1 with 1-2 hours interval. Subject will take mandatory additional clear fluid after each dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SP+MS, Day Before-Only Dosing
Description: The subject will self-administer SP+MS in the morning of Day 1 and afternoon of Day 1. Subject will take mandatory additional clear fluid after each dose.
Study: NCT00651261

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone acetate
Description: ocular medication administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone acetate
Description: ocular medication administration